Dx Deals: New Premerger Regulations Could Slow Down Pace of Transactions
The new rules, which were approved by the FTC in October and will go into effect in mid-January, aim to put a damper on consolidation
The new rules, which were approved by the FTC in October and will go into effect in mid-January, aim to put a damper on consolidation
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.
The Miami-based startup has secured major in-home phlebotomy services contracts from some of the nation’s biggest lab companies.
The Hilden, Germany-based company is extending its genetic testing profile beyond oncology to neurology biomarkers.
In a surprise move, the e-retail giant announced it will close down its Amazon Care Primary Health Services for employees at the end of 2022.
In July, ICATT took a major step toward equitable access to testing by enlisting two of the country’s leading COVID-19 PCR test providers.
Some of the lab industry’s biggest players are teaming up to develop new monkeypox diagnostics in response to the current outbreak.
A hostile government policy has done little to slow consolidation of independent medical practices and hospitals.
Companies will explore LabDroid’s capacity to automate sample preparation workflows for long-read sequencing systems.
Healthcare M&A might have bottomed out in the first quarter of 2022 in terms of both deal volume and size, according to a new report.